In case of COVID-19, MEA is highly affected especially South Africa. The healthcare sector in the UAE has undergone a considerable number of infrastructure and procedural changes to position itself as a leading healthcare provider. These improvements have been more recently recognized throughout the COVID-19 pandemic due to the continuous investments made to improve the sector’s hard and soft infrastructure. However, COVID-19 is likely to continue to have a notable impact on healthcare operations in countries. The pandemic had a major impact on a wide range of health outcomes. Disordering of elective health services related to cervical screening, management of abnormal screening test results, and treatment of pre-cancers, that lead to increase in cervical cancer incidence and inflame existing health disproportions. Since, the beginning of 2020, the pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. In many countries, diagnostics services have been disrupted, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions including cervical cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on market, limited diagnosis, and decreased access to expert gynecologists further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in cervical cancer diagnosis will increase.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA cervical cancer diagnostic testing market. The MEA cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period.